Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Five leading researchers provide their perspectives on our current understanding of pioneer factors and their important gene regulatory roles in cell differentiation, cell fate determination and reprogramming.
In this Viewpoint, we asked six experts to give their opinions on the utility of polygenic scores, their strengths and limitations, and the remaining barriers that need to be overcome for their equitable use.
In this Viewpoint, five experts discuss our biological understanding of super-enhancers, how we can responsibly study their functions, and their opinions on whether names for enhancer clusters are an informative reflection of their functional properties.
To celebrate the first 20 years of Nature Reviews Genetics, we asked 12 leading scientists to reflect on the key challenges and opportunities faced by the field of genetics and genomics.
Five experts discuss topical aspects of RNA modifications, highlighting where the research field stands, recommendations for best practices and visions for the future of epitranscriptomics studies.
Although enhancers are crucial and widespread gene-regulatory elements, we are far from a complete understanding of how they function or their importance in areas such as disease and evolution. Five prominent researchers discuss some of the key outstanding questions in enhancer biology.
How much transgenerational epigenetic inheritance takes place, and what impact does this have on organisms? We asked five leading researchers — working on key model organisms and on human disease — for their views.
We asked five experts their opinions on issues that arise from new clinical tests that are based on next-generation sequencing. Crucial gaps in infrastructure need to be addressed for the results of these tests to be optimally handled.
Is ageing in our genes? In this Viewpoint, six experts present their views on the extent to which ageing is genetic and discuss future strategies for research into ageing and longevity.
The genetic architecture of human disease is often hard to replicate in model organisms, and disease modelling in human cells is rapidly improving. Six leading model organism researchers provide their perspective on where this leaves non-human models of disease.
Direct-to-consumer (DTC) genetic tests allow individuals to learn about their health or that of their future offspring. Should we protect individuals from potentially misleading genetic information about themselves or should we assume that adults who seek DTC services can interpret the genetic findings even without the intervention of a health professional? We present five different perspectives on whether DTC genetic tests should be regulated and, if so, how.
To celebrate the first 10 years ofNature Reviews Genetics, we asked eight leading researchers for their views on the key developments in genetics and genomics in the past decade and the prospects for the future.
Seven leading geneticists express their views about where the unidentified components of the heritability for complex human diseases might lie and how this could affect the underlying genetic architecture, as well as offering suggestions of how genomic research could be targeted to address this key issue.
Four human disease geneticists express their views about the changing landscape of human disease studies and the impact of technological progress on establishing links between a pathogenic genomic variant and a disease phenotype.
The ability to generate personalized genomic information for large numbers of people is rapidly becoming a reality. Four experts provide their opinions on how useful this information is likely to be and how it should best be put to use.
Four leading researchers contribute their personal opinions on recent progress and current challenges in induced pluripotent stem cell research. Their varied perspectives suggest that for clinical applications there is cause for optimism, tempered with caution, and they highlight exciting recent advances in reprogramming and differentiation.
